Lipum AB (publ) (LIPUM.ST) Research
Lipum AB (publ) is a biopharmaceutical firm based in Sweden, focused on pioneering the discovery and development of therapeutic solutions for long-term inflammatory conditions. The company's primary therapeutic asset, SOL-116, is a humanized antibody currently in the late preclinical stage, designed to treat pediatric rheumatism and adult rheumatoid arthritis. To facilitate the advancement of SOL-116 into clinical trials, Lipum has established a collaboration with Pelago Bioscience AB to meticulously monitor drug targets. Founded in 2010, the company's operations are headquartered in Umeå, Sweden.
Market snapshot
- Symbol
- LIPUM.ST
- Price
- $14.35
- Day change
- +0.70%
- Market cap
- $304.4M
- P/E ratio
- -4.26x
- 52-week range
- 8.56-19.95
- Sector
- Healthcare
- Industry
- Biotechnology
Peer companies
- Alzinova AB (publ) (ALZ.ST)
- Annexin Pharmaceuticals AB (publ) (ANNX.ST)
- Bio-Works Technologies AB (publ) (BIOWKS.ST)
- Clinical Laserthermia Systems AB (publ) (CLS-B.ST)
- Enorama Pharma AB (publ) (ERMA.ST)
- Initiator Pharma A/S (INIT.ST)
- IRLAB Therapeutics AB (publ) (IRLAB-A.ST)
- Isofol Medical AB (publ) (ISOFOL.ST)
Open Lipum AB (publ) (LIPUM.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.